Category: AtheroMed Inc.
Here's a look at some of the top regulatory stories for medical device companies this week: Seven questions raised by Medtronic's $43B Covidien acquisition; Medtronic, Covidien merger: Good or bad for medtech innovation?; Medtronic, Covidien merger: Mass. Gov. Deval Patrick says he's had no contact with either company; Volcano closes $117M AtheroMed buy; Incubator group buys prostate treatment tech from Endo Health.
Volcano pays nearly $117 million in cash and puts another $15 million on the table in milestones for AtheroMed and its Phoenix atherectomy catheter system.
Volcano (NSDQ:VOLC) said yesterday that it closed the buyout of AtheroMed and its Phoenix atherectomy catheter system, paying out roughly $116.5 million in cash but netting about $1.7 million in cash on hand from AtheroMed.
Volcano Corp. continues to broaden its peripheral portfolio with the $115 million acquisition of FDA-cleared atherectomy systems maker AtheroMed.
Volcano (NSDQ:VOLC) hopes to change its reputation with the $115 million acquisition of privately held AtheroMed and its Phoenix atherectomy catheter system.
AtheroMed lands 510(k) clearance from the FDA for its Phoenix atherectomy system, used for treating peripheral artery disease.
AtheroMed secured 510(k) clearance from the FDA for its Phoenix device, an atherectomy catheter used for treating peripheral artery disease.
The low-profile catheter aims to minimizes vessel interaction and designed to be easy to set up. The Phoenix system features front-cutting technology that cuts while clearing away clearing debris with an internal Archimedes screw, which runs the length of the catheter. The device is available in a variety of sizes, according to a press release.
California-based AtheroMed is just shy of raising $4.5 million through an offering of debt, options, warrants and other securities.
AtheroMed is closing in on a $4.5 million fundraising round, offering debt and options offering, SEC documents show.
The Menlo Park, Calif.-based medical device company has so far raised $4.3 million for its operations, according to a regulatory filing.
AtheroMed, which is developing an atherectomy device to treat peripheral artery disease, reports a $6 million funding round.
AtheroMed said it's raised a $6 million equity round, taking its total funding raise since 2009 to $20 million, according to regulatory filings.
The Menlo Park, Calif.-based medical device company is developing an atherectomy device for treating peripheral artery disease, according to its website.
AtheroMed is still flying under the radar, to judge by the 1-page website, which provides only an email link to contact the company.